How much revenue does Wuhan YZY Biopharma make?

Wuhan YZY Biopharma reported 66.86 million CNY in revenue for fiscal year 2025, down 38.0% from 107.81 million CNY in fiscal year 2024.

What companies are similar to Wuhan YZY Biopharma?

Listed companies of a similar size in the same industry (additional cancer treatment drugs) include Immuneonco-b (1541.HK), Sunho Biologics, Inc. (2898.HK), 3D Medicines (1244.HK), Immunotech Biopharm Ltd (6978.HK).

Wuhan YZY Biopharma Co., Ltd. (2496.HK) Stock

About Wuhan YZY Biopharma Co., Ltd.

Wuhan YZY Biopharma Co., Ltd., a biotechnology company, develops bispecific antibody-based therapies for the treatment of cancer, cancer-associated complications, and age-related ophthalmologic diseases. It develops various product candidates for the treatment of malignant ascites, malignant pleural effusion, solid tumors, pancreatic cancer, hepatocellular carcinoma, and other advanced solid tumor...

At a glance

Wuhan YZY Biopharma reported revenue of 66.86 million CNY for fiscal year 2025, down 38.0% from fiscal year 2024, and net income of -84.73 million CNY.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.